|
5LEV
Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) (V264G mutant)
Deposited 2016-06-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–408(408 aa)
|
Mutation:V264G
|
UNL UNKNOWN LIGAND × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 9;293 K;0.1M bicine pH 9.0, 0.05M sodium chloride, 38% PEG300, 5mM Na2WO4
|
Resolution 3.20 Å
R-free 0.240
|
|
5O5E
Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) (V264G mutant) in complex with tunicamycin
Deposited 2017-06-01
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–408(408 aa)
|
Mutation:V264G
|
P6L (2S)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(6E)-HEXADEC-6-ENOYLOXY]PROPYL (8E)-OCTADEC-8-ENOATE × 2
9LH Tunicamycin × 2
UNL UNKNOWN LIGAND × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;277 K;0.1M bicine pH 8.5 -- 0.05M sodium chloride -- 36% PEG200
|
Resolution 3.40 Å
R-free 0.236
|
|
6BW5
Human GPT (DPAGT1) in complex with tunicamycin
Deposited 2017-12-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–408(408 aa)
Chain B
1–408(408 aa)
|
Not recorded
|
TUM Tunicamycin × 2
PGW (1R)-2-{[(S)-{[(2S)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(hexadecanoyloxy)methyl]ethyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;290 K;PEG400, calcium chloride
|
Resolution 3.10 Å
R-free 0.288
|
|
6BW5
Human GPT (DPAGT1) in complex with tunicamycin
Deposited 2017-12-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain C
1–408(408 aa)
Chain D
1–408(408 aa)
|
Not recorded
|
TUM Tunicamycin × 2
PGW (1R)-2-{[(S)-{[(2S)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(hexadecanoyloxy)methyl]ethyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;290 K;PEG400, calcium chloride
|
Resolution 3.10 Å
R-free 0.288
|
|
6BW6
Human GPT (DPAGT1) H129 variant in complex with tunicamycin
Deposited 2017-12-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–408(408 aa)
Chain B
1–408(408 aa)
|
Not recorded
|
TUM Tunicamycin × 2
PGW (1R)-2-{[(S)-{[(2S)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(hexadecanoyloxy)methyl]ethyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;290 K;PEG400, calcium chloride
|
Resolution 2.95 Å
R-free 0.291
|
|
6BW6
Human GPT (DPAGT1) H129 variant in complex with tunicamycin
Deposited 2017-12-14
|
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain C
1–408(408 aa)
Chain D
1–408(408 aa)
|
Not recorded
|
TUM Tunicamycin × 2
PGW (1R)-2-{[(S)-{[(2S)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(hexadecanoyloxy)methyl]ethyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;290 K;PEG400, calcium chloride
|
Resolution 2.95 Å
R-free 0.291
|
|
6FM9
Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1)
Deposited 2018-01-30
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–408(408 aa)
|
Not recorded
|
P6L (2S)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(6E)-HEXADEC-6-ENOYLOXY]PROPYL (8E)-OCTADEC-8-ENOATE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;0.05M ADA pH 6.5 -- 24% PEG400
|
Resolution 3.60 Å
R-free 0.270
|
|
6FWZ
Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) (V264G mutant) in complex with UDP-GlcNAc
Deposited 2018-03-07
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–408(408 aa)
|
Mutation:V264G
|
MG MAGNESIUM ION × 2
UD1 URIDINE-DIPHOSPHATE-N-ACETYLGLUCOSAMINE × 2
UNL UNKNOWN LIGAND × 2
P6L (2S)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(6E)-HEXADEC-6-ENOYLOXY]PROPYL (8E)-OCTADEC-8-ENOATE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 9;293 K;0.1M bicine pH 9.0 -- 0.05M sodium chloride -- 37.5% PEG300
|
Resolution 3.10 Å
R-free 0.236
|